Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

BACKGROUND: With this study, we sought to characterise the impact of pro-inflammatory cytokines on the outcomes of gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC). METHODS: Treatment-naive patients with advanced PC and no obvious infections were eligible for enrolment. All of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsunaga, S, Ikeda, M, Shimizu, S, Ohno, I, Furuse, J, Inagaki, M, Higashi, S, Kato, H, Terao, K, Ochiai, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670479/
https://www.ncbi.nlm.nih.gov/pubmed/23591198
http://dx.doi.org/10.1038/bjc.2013.174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670479/
https://www.ncbi.nlm.nih.gov/pubmed/23591198
http://dx.doi.org/10.1038/bjc.2013.174

Ejemplares similares